{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:15:53Z","timestamp":1790511353824,"version":"4.1.0"},"reference-count":183,"publisher":"Elsevier","isbn-type":[{"value":"9780444642776","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmch.2018.12.002","type":"book-chapter","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T22:21:41Z","timestamp":1552342901000},"page":"1-62","source":"Crossref","is-referenced-by-count":36,"title":["Covalent binders in drug discovery"],"prefix":"10.1016","author":[{"given":"Anil","family":"Vasudevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Argiriadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Baranczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gavrilyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian D.","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hulce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmch.2018.12.002_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/anie.201611914","article-title":"New modalities for challenging targets in drug discovery","volume":"56","author":"Valeur","year":"2017","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2017.06.005","article-title":"Choose and use your chemical probe wisely to explore cancer biology","volume":"32","author":"Blagg","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0025","first-page":"195","article-title":"Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo","volume":"187","author":"Jollow","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0030","series-title":"Comprehensive natural products chemistry","author":"Nakanishi","year":"1999"},{"issue":"6","key":"10.1016\/bs.pmch.2018.12.002_bb0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7164\/antibiotics.36.639","article-title":"Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization","volume":"36","author":"Hamamoto","year":"1983","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/JB.58.4.527-529.1949","article-title":"An antiphage agent isolated from Aspergillus Sp","volume":"58","author":"Hanson","year":"1949","journal-title":"J Bacteriol"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.002_bb0045","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7164\/antibiotics.45.1746","article-title":"Epoxomicin, a new antitumor agent of microbial origin","volume":"45","author":"Hanada","year":"1992","journal-title":"J Antibiot (Tokyo)"},{"issue":"6","key":"10.1016\/bs.pmch.2018.12.002_bb0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/c2np20012k","article-title":"Electrophilic natural products and their biological targets","volume":"29","author":"Gersch","year":"2012","journal-title":"Nat Prod Rep"},{"issue":"36","key":"10.1016\/bs.pmch.2018.12.002_bb0055","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1002\/anie.200500900","article-title":"Protein-reactive natural products","volume":"44","author":"Drahl","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1021\/cr030102i","article-title":"Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity","volume":"105","author":"Fisher","year":"2005","journal-title":"Chem Rev"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0065","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0021-9258(18)52203-1","article-title":"The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase","volume":"266","author":"Hadvary","year":"1991","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/bs.pmch.2018.12.002_bb0070","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.1073\/pnas.95.21.12153","article-title":"The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase","volume":"95","author":"Lowther","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.002_bb0075","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1073\/pnas.94.12.6099","article-title":"The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2","volume":"94","author":"Sin","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0014-5793(95)00888-G","article-title":"The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1","volume":"371","author":"MacKintosh","year":"1995","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.002_bb0085","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","article-title":"Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.002_bb0090","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/jm00158a001","article-title":"The mechanism of action of the gastric acid secretion inhibitor omeprazole","volume":"29","author":"Lindberg","year":"1986","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00005344-199702000-00013","article-title":"CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury","volume":"29","author":"Rebello","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/med.21312","article-title":"Peptide-based proteasome inhibitors in anticancer drug design","volume":"34","author":"Micale","year":"2014","journal-title":"Med Res Rev"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_bb0105","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/jm00009a012","article-title":"Characterization of a class of peptide boronates with neutral P1 side-chains as highly selective inhibitors of thrombin","volume":"38","author":"Deadman","year":"1995","journal-title":"J Med Chem"},{"issue":"31","key":"10.1016\/bs.pmch.2018.12.002_bb0110","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1021\/bi963054n","article-title":"Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping","volume":"36","author":"Landro","year":"1997","journal-title":"Biochemistry"},{"issue":"25","key":"10.1016\/bs.pmch.2018.12.002_bb0115","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1021\/bi980313v","article-title":"Product inhibition of the hepatitis C virus NS3 protease","volume":"37","author":"Steinkuhler","year":"1998","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152606776056706","article-title":"Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease","volume":"6","author":"Lin","year":"2006","journal-title":"Infect Disord Drug Targets"},{"issue":"22","key":"10.1016\/bs.pmch.2018.12.002_bb0125","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1021\/jm100762r","article-title":"Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore","volume":"53","author":"Fleming","year":"2010","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1110\/ps.073253208","article-title":"Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation","volume":"17","author":"Metzler","year":"2008","journal-title":"Protein Sci"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"24","key":"10.1016\/bs.pmch.2018.12.002_bb0140","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","article-title":"The taxonomy of covalent inhibitors","volume":"57","author":"Tuley","year":"2018","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/tx2003257","article-title":"Application of the hard and soft, acids and bases (HSAB) theory to toxicant--target interactions","volume":"25","author":"Lopachin","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1593\/tlo.12187","article-title":"The scarlet letter of alkylation: a mini review of selective alkylating agents","volume":"5","author":"Oronsky","year":"2012","journal-title":"Transl Oncol"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0155","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1074\/jbc.M411325200","article-title":"Evidence that the fosfomycin target Cys(115) in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release","volume":"280","author":"Eschenburg","year":"2005","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/bs.pmch.2018.12.002_bb0160","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0165","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1021\/jm501636x","article-title":"Design, synthesis, and biological evaluation of tetrazole analogs of CI-amidine as protein arginine deiminase inhibitors","volume":"58","author":"Subramanian","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0010-8545(90)85016-L","article-title":"Hard and soft acids and bases\u2014the evolutioin of a chemical concept","volume":"100","author":"Pearson","year":"1990","journal-title":"Coord Chem Rev"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr Opin Chem Biol"},{"issue":"5726","key":"10.1016\/bs.pmch.2018.12.002_bb0180","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0185","first-page":"3","article-title":"Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer","volume":"15","author":"Fry","year":"2000","journal-title":"Anticancer Drug Des"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0190","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bbrc.2016.08.109","article-title":"Cysteinome: the first comprehensive database for proteins with targetable cysteine and their covalent inhibitors","volume":"478","author":"Wu","year":"2016","journal-title":"Biochem Bioph Res Commun"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1367-5931(99)00049-6","article-title":"Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs","volume":"4","author":"Way","year":"2000","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/17460441.2016.1115478","article-title":"New drug design with covalent modifiers","volume":"11","author":"Adeniyi","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr Opin Chem Biol"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.002_bb0210","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1074\/jbc.M114.614891","article-title":"Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694","volume":"290","author":"Zhong","year":"2015","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.002_bb0215","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10822-015-9857-0","article-title":"Automated computational screening of the thiol reactivity of substituted alkenes","volume":"29","author":"Smith","year":"2015","journal-title":"J Comput Aided Mol Des"},{"issue":"8\u20139","key":"10.1016\/bs.pmch.2018.12.002_bb0220","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ijch.201300144","article-title":"From catalytic mechanism to rational design of reversible covalent inhibitors of serine and cysteine hydrolases","volume":"54","author":"Shokhen","year":"2014","journal-title":"Isr J Chem"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0225","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","article-title":"Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects","volume":"73","author":"Li","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"26","key":"10.1016\/bs.pmch.2018.12.002_bb0230","doi-asserted-by":"crossref","first-page":"14694","DOI":"10.1073\/pnas.96.26.14694","article-title":"Activity-based protein profiling: the serine hydrolases","volume":"96","author":"Liu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1039\/C3CC46002A","article-title":"Beta-Sultams exhibit discrete binding preferences for diverse bacterial enzymes with nucleophilic residues","volume":"50","author":"Kolb","year":"2014","journal-title":"Chem Commun (Camb)"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_rf0240","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_rf0245","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/ja993588m","article-title":"Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of \u03b1\u2018,\u03b2\u2018-epoxyketone proteasome inhibitors","volume":"122","author":"Groll","year":"2000","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0245","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1039\/C6MD00017G","article-title":"Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-alpha-acetyl-L-lysine as an amine nucleophile","volume":"7","author":"Dahal","year":"2016","journal-title":"MedChemComm"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_rf0255","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1097-2765(05)00089-4","article-title":"Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine","volume":"6","author":"Walker","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/bs.pmch.2018.12.002_rf0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cbpa.2018.05.011","article-title":"Beyond cysteine: recent developments in the area of targeted covalent inhibition","volume":"44","author":"Mukherjee","year":"2018","journal-title":"Curr Opin Chem Biol"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_bb0255","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","article-title":"Identification and characterization of an irreversible inhibitor of CDK2","volume":"22","author":"Anscombe","year":"2015","journal-title":"Chem Biol"},{"issue":"5392","key":"10.1016\/bs.pmch.2018.12.002_bb0260","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.282.5392.1324","article-title":"Structure of human methionine aminopeptidase-2 complexed with fumagillin","volume":"282","author":"Liu","year":"1998","journal-title":"Science"},{"issue":"15","key":"10.1016\/bs.pmch.2018.12.002_bb0265","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1021\/acs.jmedchem.8b00305","article-title":"Novel modes of inhibition of wild-type Isocitrate dehydrogenase 1 (IDH1): direct covalent modification of His315","volume":"61","author":"Jakob","year":"2018","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0270","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cbi.2009.03.018","article-title":"Covalent binding of the organophosphorus agent FP-biotin to tyrosine in eight proteins that have no active site serine","volume":"180","author":"Grigoryan","year":"2009","journal-title":"Chem Biol Interact"},{"issue":"32","key":"10.1016\/bs.pmch.2018.12.002_bb0275","doi-asserted-by":"crossref","first-page":"11881","DOI":"10.1021\/la3022003","article-title":"Control of enzyme-solid interactions via chemical modification","volume":"28","author":"Chowdhury","year":"2012","journal-title":"Langmuir"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1747-0285.2009.00907.x","article-title":"The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor","volume":"75","author":"Fernandez","year":"2010","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0285","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrd1720","article-title":"Elucidating mechanisms of drug-induced toxicity","volume":"4","author":"Liebler","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0290","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1039\/c3tx50027f","article-title":"High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds","volume":"2","author":"Naven","year":"2013","journal-title":"Toxicol Res"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0295","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.tiv.2008.03.006","article-title":"Mass spectrometric identification of covalent adducts of the skin allergen 2,4-dinitro-1-chlorobenzene and model skin proteins","volume":"22","author":"Aleksic","year":"2008","journal-title":"Toxicol In Vitro"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.002_bb0300","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem Soc Rev"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0305","series-title":"Biomedical chemistry: current trends and developments","first-page":"44","article-title":"Designing covalent inhibitors: a medicinal chemistry challenge","author":"Lopes","year":"2016"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/BJ20140793","article-title":"Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding","volume":"465","author":"Visperas","year":"2015","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0315","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_bb0320","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nchembio.1582","article-title":"A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors","volume":"10","author":"Lanning","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"30","key":"10.1016\/bs.pmch.2018.12.002_bb0325","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1002\/anie.201802693","article-title":"Reactive chemical probes: beyond the kinase cysteinome","volume":"57","author":"Jones","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0330","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/bs.pmch.2018.12.002_bb0335","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0340","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2018","journal-title":"Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0345","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1002\/anie.201707875","article-title":"The cysteinome of protein kinases as a target in drug development","volume":"57","author":"Chaikuad","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2010.02.007","article-title":"A structure-guided approach to creating covalent FGFR inhibitors","volume":"17","author":"Zhou","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_rf0365","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/cb500674s","article-title":"DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors","volume":"10","author":"Huang","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"45","key":"10.1016\/bs.pmch.2018.12.002_rf0370","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0360","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0365","unstructured":"Friedman, M. n.d. (Oral presentation) Kinase Inhibitor Chemistry Conference, San Diego, CA 4\/25\/2017."},{"key":"10.1016\/bs.pmch.2018.12.002_bb0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-61779-465-0_2","article-title":"Analysis of protein binding sites by computational solvent mapping","volume":"819","author":"Hall","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0375","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/prot.20660","article-title":"Very fast empirical prediction and rationalization of protein pKa values","volume":"61","author":"Li","year":"2005","journal-title":"Proteins"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0380","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0006-3495(02)73940-4","article-title":"Combining conformational flexibility and continuum electrostatics for calculating pKas in proteins","volume":"83","author":"Georgescu","year":"2002","journal-title":"Biophys J"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0385","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbapap.2017.05.009","article-title":"Modeling covalent-modifier drugs","volume":"1865","author":"Awooner-Williams","year":"2017","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0390","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/acs.jcim.8b00454","article-title":"How reactive are druggable cysteines in protein kinases?","volume":"58","author":"Awooner-Williams","year":"2018","journal-title":"J Chem Inf Model"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0395","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1021\/jm501412a","article-title":"Chemical and computational methods for the characterization of covalent reactive groups for prospective design of irreversible inhibitors","volume":"57","author":"Flanagan","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0400","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J Chem Inf Model"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0405","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","article-title":"Tricycle covalent inhibitors selectively target Jak3 through an active site thiol","volume":"290","author":"Goedken","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0410","unstructured":"Hoemann, M. n.d. (Oral presentation) 25th Enzyme and Mechanisms Conference, St. Petersburg Beach, FL 1\/6\/2017."},{"key":"10.1016\/bs.pmch.2018.12.002_bb0415","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/ci500681r","article-title":"DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment","volume":"55","author":"Scholz","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0420","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1021\/jm3002839","article-title":"Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells","volume":"55","author":"de Cesco","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0425","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1021\/acs.jctc.7b00764","article-title":"Automated transition state search and its application to diverse types of organic reactions","volume":"13","author":"Jacobson","year":"2017","journal-title":"J Chem Theory Comput"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_bb0430","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1039\/b905821b","article-title":"The topology of drug\u2013target interaction networks: implicit dependence on drug properties and target families","volume":"5","author":"Mestres","year":"2009","journal-title":"Mol Biosyst"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0435","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nature03193","article-title":"Navigating chemical space for biology and medicine","volume":"432","author":"Lipinski","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0440","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/jm8008597","article-title":"Covalent modifiers: an orthogonal approach to drug design","volume":"52","author":"Potashman","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0445","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/bs.pmch.2018.12.002_bb0450","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17460441.2012.688744","article-title":"Drug discovery for a new generation of covalent drugs","volume":"7","author":"Kalgutkar","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0455","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0460","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/molecules20021984","article-title":"Theory and applications of covalent docking in drug discovery: merits and pitfalls","volume":"20","author":"Kumalo","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0465","unstructured":"A. Phillippidis, Genetic engineering and biotechnology news, 2018. Published online: 20 December 2013 \u00a9 Springer Science+Business Media New York 2013."},{"key":"10.1016\/bs.pmch.2018.12.002_bb0480","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0485","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"Vivanco","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0490","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials","volume":"9","author":"Burger","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.002_bb0495","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/tx0499259","article-title":"Organophosphate toxicology: safety aspects of nonacetylcholinesterase secondary targets","volume":"17","author":"Casida","year":"2004","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.002_bb0500","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1074\/jbc.272.12.7595","article-title":"Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease","volume":"272","author":"Pi\u00f1eiro-S\u00e1nchez","year":"1997","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/bs.pmch.2018.12.002_bb0505","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/bi002579j","article-title":"Profiling serine hydrolase activities in complex proteomes","volume":"40","author":"Kidd","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0510","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nmeth778","article-title":"A streamlined platform for high-content functional proteomics of primary human specimens","volume":"2","author":"Jessani","year":"2005","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0515","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd3620","article-title":"The pharmacological landscape and therapeutic potential of serine hydrolases","volume":"11","author":"Bachovchin","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/bs.pmch.2018.12.002_bb0520","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1021\/cb400261h","article-title":"Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition","volume":"8","author":"Chang","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0525","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12345","article-title":"A chemical proteomic atlas of brain serine hydrolases identifies cell type-specific pathways regulating neuroinflammation","volume":"5","author":"Viader","year":"2016","journal-title":"Elife"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0530","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/acs.jproteome.8b00500","article-title":"Activity-based protein profiling of intraoperative serine hydrolase activities during cardiac surgery","volume":"17","author":"Navarrete","year":"2018","journal-title":"J Proteome Res"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1559-0275-10-17","article-title":"Proteomic characterization of serine hydrolase activity and composition in normal urine","volume":"10","author":"Navarrete","year":"2013","journal-title":"Clin Proteomics"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.002_bb0540","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1021\/acs.molpharmaceut.5b00414","article-title":"Substrate-competitive activity-based profiling of ester prodrug activating enzymes","volume":"12","author":"Xu","year":"2015","journal-title":"Mol Pharm"},{"issue":"6342","key":"10.1016\/bs.pmch.2018.12.002_bb0545","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0550","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nchembio.1578","article-title":"A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity","volume":"10","author":"Bachovchin","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0555","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-biochem-060713-035352","article-title":"Activity-based profiling of proteases","volume":"83","author":"Sanman","year":"2014","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.002_bb0560","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1074-5521(00)00014-4","article-title":"Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools","volume":"7","author":"Greenbaum","year":"2000","journal-title":"Chem Bio"},{"issue":"27","key":"10.1016\/bs.pmch.2018.12.002_bb0565","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1073\/pnas.0402784101","article-title":"Activity-based probes for the proteomic profiling of metalloproteases","volume":"101","author":"Saghatelian","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0570","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1016\/S0021-9258(18)34279-0","article-title":"Inhibition of leucine aminopeptidase by amino acid hydroxamates","volume":"257","author":"Chan","year":"1982","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0575","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/bi00270a034","article-title":"Structural analysis of the inhibition of thermolysin by an active-site-directed irreversible inhibitor","volume":"22","author":"Holmes","year":"1983","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.002_bb0580","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/febs.14089","article-title":"Introduction to the special issue on proteases and proteolysis in health and disease","volume":"284","author":"Bogyo","year":"2017","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0585","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mol.107.039511","article-title":"Effect of cathepsin K inhibitor basicity on in vivo off-target activities","volume":"73","author":"Desmarais","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0590","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nchembio.91","article-title":"Disparate proteome reactivity profiles of carbon electrophiles","volume":"4","author":"Weerapana","year":"2008","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0595","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nature09472","article-title":"Quantitative reactivity profiling predicts functional cysteines in proteomes","volume":"468","author":"Weerapana","year":"2010","journal-title":"Nature"},{"issue":"36","key":"10.1016\/bs.pmch.2018.12.002_bb0600","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1039\/C8CC01485J","article-title":"Cysteine-reactive probes and their use in chemical proteomics","volume":"54","author":"Hoch","year":"2018","journal-title":"Chem Commun"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0605","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cell.2017.08.051","article-title":"Chemical proteomics identifies druggable vulnerabilities in a genetically defined cancer","volume":"171","author":"Bar-Peled","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.002_bb0610","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chembiol.2017.08.013","article-title":"Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products","volume":"24","author":"Grossman","year":"2017","journal-title":"Cell Chem Biol"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.002_bb0615","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.chembiol.2017.08.017","article-title":"Proteome-wide map of targets of T790M-EGFR-directed covalent inhibitors","volume":"24","author":"Niessen","year":"2017","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1073\/pnas.1313733111","article-title":"Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance","volume":"111","author":"Schwartz","year":"2014","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0625","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0630","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nature15729","article-title":"\u25b3F508 CFTR interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.002_bb0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0167-4838(83)90085-7","article-title":"Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three \u03b3-chain types with distinct molecular weights","volume":"744","author":"Francis","year":"1983","journal-title":"Biochim Biophys Acta Protein Struct Mol Enzymol"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0640","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/mas.20082","article-title":"Chemical cross-linking and mass spectrometry to map three-dimensional protein structures and protein-protein interactions","volume":"25","author":"Sinz","year":"2006","journal-title":"Mass Spectrom Rev"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0645","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nchem.2826","article-title":"Global profiling of lysine reactivity and ligandability in the human proteome","volume":"9","author":"Hacker","year":"2017","journal-title":"Nat Chem"},{"issue":"16","key":"10.1016\/bs.pmch.2018.12.002_bb0650","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1021\/ja034490h","article-title":"Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3+2] cycloaddition","volume":"125","author":"Speers","year":"2003","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/bs.pmch.2018.12.002_bb0655","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.chembiol.2015.05.018","article-title":"Selective N-hydroxyhydantoin carbamate inhibitors of mammalian serine hydrolases","volume":"22","author":"Cognetta","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0660","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nmeth.2368","article-title":"Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells","volume":"10","author":"Hulce","year":"2013","journal-title":"Nat Methods"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.002_bb0665","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.chembiol.2004.03.012","article-title":"Profiling enzyme activities in vivo using click chemistry methods","volume":"11","author":"Speers","year":"2004","journal-title":"Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0670","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/9780470559277.ch090138","article-title":"Activity-based protein profiling (ABPP) and click chemistry (CC)\u2013ABPP by MudPIT mass spectrometry","volume":"1","author":"Speers","year":"2009","journal-title":"Curr Protoc Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0675","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cbpa.2014.07.015","article-title":"Turning the spotlight on protein\u2013lipid interactions in cells","volume":"21","author":"Peng","year":"2014","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.002_bb0680","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2016.12.029","article-title":"Ligand and target discovery by fragment-based screening in human cells","volume":"168","author":"Parker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0685","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nchembio.1340","article-title":"A propofol binding site on mammalian GABAA receptors identified by photolabeling","volume":"9","author":"Yip","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0690","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1038\/srep07724","article-title":"Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach","volume":"5","author":"Su","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0695","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1038\/ncomms13042","article-title":"Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of \u03b2-secretase inhibitors","volume":"7","author":"Zuhl","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0700","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccell.2016.09.008","article-title":"An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers","volume":"30","author":"Villa","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0705","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody\u2013drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0710","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0715","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40495-018-0122-9","article-title":"Challenges of antibody drug conjugates in cancer therapy: current understanding of mechanisms and future strategies","volume":"4","author":"Lin","year":"2018","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0720","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7164\/antibiotics.42.558","article-title":"Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties","volume":"42","author":"Maiese","year":"1989","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0725","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/ja00757a071","article-title":"p-Benzyne. Generation as an intermediate in a thermal isomerization reaction and trapping evidence for the 1,4-benzenediyl structure","volume":"94","author":"Jones","year":"1972","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0730","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/199501a0","article-title":"\u2018Refuin\u2019: a non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete","volume":"199","author":"Tendler","year":"1963","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0735","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumor antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0740","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/jm00052a012","article-title":"Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand crosslinking","volume":"37","author":"Jenkins","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0745","first-page":"737","article-title":"Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity","volume":"44","author":"Gregson","year":"2001","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0750","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD) containing antibody\u2013drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0755","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/med.20212","article-title":"Biosynthesis, synthesis and biological activities of pyrrolobenzodiazepines","volume":"32","author":"Gerratana","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0760","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody\u2013drug conjugates with self-immolative disulfide linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0765","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody\u2212drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0770","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-cd70 antibody\u2013drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconj Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0775","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1021\/acs.jmedchem.7b00736","article-title":"Pyrrolobenzodiazepine dimer antibody-drug conjugates: synthesis and evaluation of noncleavable drug-linkers","volume":"60","author":"Gregson","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0780","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/acs.molpharmaceut.8b00431","article-title":"Exploration of pyrrolobenzodiazepine (PBD)-dimers containing disulfide-based prodrugs as payloads for antibody-drug conjugates","volume":"15","author":"Pei","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0785","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1016\/j.bmc.2004.07.045","article-title":"Design, synthesis, and evaluation of mixed imine\u2013amine pyrrolobenzodiazepine dimers with efficient DNA binding affinity and potent cytotoxicity","volume":"12","author":"Kamal","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0790","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A new class of antibody\u2013drug conjugates with potent DNA alkylating activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0795","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.7164\/antibiotics.31.1211","article-title":"CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism","volume":"31","author":"Hanka","year":"1978","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0800","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1016\/S0040-4039(00)97278-2","article-title":"Covalent alkylation of DNA with duocarmycin A. Identification of a basic site structure","volume":"31","author":"Sugiyama","year":"1990","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0805","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/anie.199614381","article-title":"CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies","volume":"35","author":"Boger","year":"1996","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0810","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7164\/antibiotics.37.63","article-title":"Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065","volume":"37","author":"McGovren","year":"1984","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0815","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0820","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody\u2013drug conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0825","unstructured":"Maderna, A.; Doroski, M. D.; Chen, Z.; Risley, H. L.; Casavant, J. M.; O'Donnell, C. J.; Porte, A. M.; Subramanyam, C. Preparation of bifunctional cytotoxic agents including drug dimers and antibody conjugates for treating cancer. n.d. WO 2015110935."},{"key":"10.1016\/bs.pmch.2018.12.002_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","article-title":"Mechanism of action of camptothecin","volume":"922","author":"Liu","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0835","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/mrc.4508","article-title":"Preliminary study of mechanism of action of SN38 derivatives. Physicochemical data, evidence of interaction and alkylation of DNA octamer d(GCGATCGC)2","volume":"55","author":"Naumczuk","year":"2017","journal-title":"Magn Reson Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0840","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"8","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0845","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.2000.tb07022.x","article-title":"Dependence of anticancer activity of camptothecins on maintaining their lactone function","volume":"922","author":"Giovanella","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0850","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1021\/jo000221n","article-title":"20-O-acylcamptothecin derivatives: evidence for lactone stabilization 1","volume":"65","author":"Zhao","year":"2000","journal-title":"J Org Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0855","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1039\/C5NP00110B","article-title":"Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1","volume":"33","author":"Pham","year":"2016","journal-title":"Nat Prod Rep"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0860","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1535-7163.MCT-09-0051","article-title":"Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells","volume":"8","author":"Albert","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0865","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/chem.201002402","article-title":"Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464","volume":"17","author":"Osman","year":"2011","journal-title":"Chem Eur J"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0870","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acs.bioconjchem.6b00291","article-title":"Natural product splicing inhibitors: a new class of antibody\u2013drug conjugate (ADC) payloads","volume":"27","author":"Puthenveetil","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0875","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178452","article-title":"Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thailanstatin antibody drug conjugate","volume":"12","author":"Puthenveetil","year":"2017","journal-title":"PLos One"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0880","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nchembio.2051","article-title":"AIG1 and ADTRP are atypical integral membrane hydrolases that degrade bioactive FAHFAs","volume":"12","author":"Parsons","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.002_bb0885","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1039\/C7CS00607A","article-title":"Chemical methods for mapping cysteine oxidation","volume":"47","author":"Alcock","year":"2018","journal-title":"Chem Soc Rev"},{"issue":"50","key":"10.1016\/bs.pmch.2018.12.002_bb0890","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/bi301441e","article-title":"Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation","volume":"51","author":"Truong","year":"2012","journal-title":"Biochem"},{"issue":"7","key":"10.1016\/bs.pmch.2018.12.002_bb0895","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.chembiol.2016.05.017","article-title":"Molecular basis for redox activation of epidermal growth factor receptor kinase","volume":"23","author":"Truong","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"23","key":"10.1016\/bs.pmch.2018.12.002_bb0900","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1021\/jacs.6b02960","article-title":"Arylfluorosulfates inactivate intracellular lipid binding protein(s) through chemoselective SuFEx reaction with a binding site Tyr residue","volume":"138","author":"Chen","year":"2016","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2018.12.002_bb0905","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"\u00c1br\u00e1nyi-Balogh","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.002_bb0910","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.002_bb0915","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Akcay","year":"2016","journal-title":"Nat Chem Biol"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007964681830016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007964681830016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T17:33:33Z","timestamp":1663090413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007964681830016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780444642776"],"references-count":183,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2018.12.002","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}